Bijblijven

, Volume 30, Issue 3, pp 54–60 | Cite as

Nierinsufficiëntie en medicatie

  • Anne Esselink
  • Nynke (D.) Scherpbier-de Haan
  • Kees Kramers
Artikelen
First Online:
  • 173 Downloads

Samenvatting

In de huisartsenpraktijk neemt het aantal patiënten met een verminderde nierfunctie toe. Veel geneesmiddelen worden renaal uitgescheiden, wat onder andere consequenties heeft voor de dosering van deze geneesmiddelen. Het is in de dagelijkse praktijk niet altijd gemakkelijk hiermee om te gaan. In deze bijdrage gaan we dieper in op de beoordeling van de nierfunctie en geven we vervolgens achtergrondinformatie en praktische adviezen omtrent het gebruik van antibiotica, orale antidiabetica, ACE-remmers, NSAID’s, diuretica en de nieuwe directe orale anticoagulantia (DOAC) bij nierinsufficiëntie.

This is a preview of subscription content, log in to check access.

Literatuur

  1. 1.
    Harm-rapport (Hospital Admissions Related to Medication). Utrecht: Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology & Pharmacotherapy, November 2006.Google Scholar
  2. 2.
    Leendertse AJ, Dijk EA van, Smet PA de, Egberts TC, Bemt PM van den. Contribution of renal impairment to potentially preventable medication-related hospital admissions. Ann Pharmacother 2012 May;46(5):625–33.PubMedCrossRefGoogle Scholar
  3. 3.
    Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005;16:763–73.PubMedCrossRefGoogle Scholar
  4. 4.
    Verhave JC, Kramers C, Wetzels JFM. Nieuwe formule leidt tot betere schattingen. Pharm Weekbl 2007;142(40):18–21.Google Scholar
  5. 5.
    Felts JH, Hayes DM, Gergen JA, Toole JF. Neural, hematologic and bacteriologic effects of nitrofurantoin in renal insufficiency. Am J Med 1971;51:331–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Thieler H, Meyer W. Nil nocere! Severe polyneuropathy during nitrofurantoin therapy of renal insufficiency. Dtsch Gesundheitsw 1968;23:488–91.PubMedGoogle Scholar
  7. 7.
    Geerts AF, et al. Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care. Eur J Clin Pharmacol 2013 Sep;69(9):1701–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Siber GR, Gorham CC, Ericson JF, Smith AL. Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. Rev Infect Dis 1982 Mar-Apr;4(2):566–78.PubMedCrossRefGoogle Scholar
  9. 9.
    Rigalleau V, et al. Estimation of renal function in patients with diabetes. Diabetes Metab 2011;37(5):359–66.PubMedCrossRefGoogle Scholar
  10. 10.
    Linden CMJ van der, Knol W, Marum RJ van, Jansen PA. Lactaatacidose bij een 85-jarige vrouw door behandeling met metformine. Ned Tijdschr Geneeskd 2007;151:977–80.PubMedGoogle Scholar
  11. 11.
    Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999:489–503.Google Scholar
  12. 12.
    Graham GG, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50 (2):81–98.PubMedCrossRefGoogle Scholar
  13. 13.
    Jönsson A, Rydberg T, Sterner G, Melander A. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 1998;53:429–35.PubMedCrossRefGoogle Scholar
  14. 14.
    Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996;39:1617–24.PubMedCrossRefGoogle Scholar
  15. 15.
    Marbury TC, et al. Pharmacokinetics of repaglinide in subjects with renal impairment.Clin Pharmacol Ther 2000 Jan;67(1):7–15.PubMedCrossRefGoogle Scholar
  16. 16.
    Lam FYW, Banerji S, Hatfield C, Talbert RL. Principles of drug administration in renal insufficiency. Clin Pharmocokinet 1997 Jan;32 (1):30–57.CrossRefGoogle Scholar
  17. 17.
    Boulton D, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011 Apr;50(4):253–65.PubMedCrossRefGoogle Scholar
  18. 18.
    Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 2011;13:947–54.PubMedCrossRefGoogle Scholar
  19. 19.
    Bergman AJ, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007;30:1862–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Linneberg H, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007;64:317–27.CrossRefGoogle Scholar
  21. 21.
    Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009 Dec;68(6):898–905.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Bootsma JE, et al. Adherence to biochemical monitoring recommendations in patients starting with renin angiotensin system inhibitors: a retrospective cohort study in the Netherlands. Drug Saf 2011 Jul 1;34(7):605–14.PubMedCrossRefGoogle Scholar
  23. 23.
    Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999 May 31;106(5B):13S-24S.PubMedCrossRefGoogle Scholar
  24. 24.
    Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. New Engl J Med 1984;310:563–72.PubMedCrossRefGoogle Scholar
  25. 25.
    Niemeyer C, Hasenfuss G, Wais U, Knauf H, Schäfer-Korting M, Mutschler E. Pharmacokinetics of hydrochloorthiazide in relation to renal function. Eur J Clin Pharmacol 1983;24:661–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Traeger A, et al. Pharmacokinetic and pharmacodynamic effects of furosemide in patients with impaired renal function. Int J Clin Pharmacol Ther Toxicol 1984;22(9):481–6.PubMedGoogle Scholar
  27. 27.
    Syropoulus AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012;120(15):2954–62.CrossRefGoogle Scholar
  28. 28.
    Steffel J, Hindrick G. Apixaban in renal insufficiency: successful navigation between the Scylla and Charybdis. Eur Heart J 2012;33:2766–8.PubMedCrossRefGoogle Scholar

Copyright information

© Bohn, Stafleu van Loghum 2014

Authors and Affiliations

  • Anne Esselink
    • 1
  • Nynke (D.) Scherpbier-de Haan
    • 2
  • Kees Kramers
    • 3
  1. 1.klinisch farmacoloogRadboudumcNijmegenThe Netherlands
  2. 2.EerstelijnsvervolgopleidingenRadboudumcNijmegenThe Netherlands
  3. 3.klinisch farmacoloogCanisius-Wilhelmina ziekenhuis en RadboudumcNijmegenThe Netherlands

Personalised recommendations